Phil Tozer

Phil Tozer

Auto-generated profile, based on publicly available information

Phil Tozer

Robin Phillips’ Fistula Research Unit, St Mark’s Hospital and Academic Institute, London, UK

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2018 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
PTP. J. Tozer
P. J. Tozer
PLP. Lung
P. Lung
ALA. J. Lobo
A. J. Lobo
SSS. Sebastian
S. Sebastian
SBS. R. Brown
S. R. Brown
OCof ENiGMA Collaboration
of ENiGMA Collaboration

12 February 2015 in Colorectal Disease
Verified
Journal Article
Closed access
PDF file
PTPhilip J Tozer
Philip J Tozer
NRNeil Rayment
Neil Rayment
AHAilsa L Hart
Ailsa L Hart
NDNajib Daulatzai
Najib Daulatzai
AMAravinth U Murugananthan
Aravinth U Murugananthan
RPR. K. S. Phillips
R. K. S. Phillips

5 November 2023 in Colorectal Disease
Verified
Journal Article
Closed access
KCKatie L. R. Cross
Katie L. R. Cross
SBSteven R. Brown
Steven R. Brown
JKJos Kleijnen
Jos Kleijnen
JBJames Bunce
James Bunce
MPMelanie Paul
Melanie Paul
PTPhilip Tozer
Philip Tozer

20 May 2020 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
MKMisha Kabir
Misha Kabir
RFRishi Fofaria
Rishi Fofaria
NANaila Arebi
Naila Arebi
PBPaul Bassett
Paul Bassett
PTPhil J Tozer
Phil J Tozer
AWAna Wilson
Ana Wilson
Background: Introduction: The prognosis of dysplasia in patients with IBD is largely determined from observational studies from the pre‐videoendoscopic era (pre‐1990s) that does not reflect recent advances in endoscopic imaging and resection.Aims: To better understand the risk of synchronous colorectal cancer and metachronous advanced neoplasia (ie high‐grade dysplasia or cancer) associated with dysplasia diagnosed in the videoendoscopic era, and to stratify risk according to a lesion's morphology, endoscopic resection status or whether it was incidentally detected on biopsy of macroscopically normal colonic mucosa (ie invisible).Methods: A systematic search of original articles published between 1990 and February 2020 was performed. Eligible studies reported on incidence of advanced neoplasia at follow‐up colectomy or colonoscopy for IBD‐dysplasia patients. Quantitative and qualitative analyses were performed.Results: Thirty‐three studies were eligible for qualitative analysis (five for the meta‐analysis). Pooled estimated proportions of incidental synchronous cancers found at colectomy performed for a pre‐operative diagnosis of visible high‐grade dysplasia, invisible high‐grade dysplasia, visible low‐grade dysplasia and invisible low‐grade dysplasia were 13.7% (95% CI 0.0‐54.1), 11.4% (95% CI 4.6‐20.3), 2.7% (95% CI 0.0‐7.1) and 2.4% (95% CI 0.0‐8.5) respectively. The lowest incidences of metachronous advanced neoplasia, for dysplasia not managed with immediate colectomy but followed up with surveillance, tended to be reported by the studies where high definition imaging and/or chromoendoscopy was used and endoscopic resection of visible dysplasia was histologically confirmed.Conclusions: The prognosis of IBD‐dysplasia diagnosed in the videoendoscopic era appears to have been improved but the quality of evidence remains low. Larger, prospective studies are needed to guide management.PROSPERO registration no: CRD42019105736.

8 June 2020 in Gut
Verified
Journal Article
Open access
PDF file
SDShahida Din
Shahida Din
AKAlexandra Kent
Alexandra Kent
RPRichard Pollok
Richard Pollok
SMSusanna Meade
Susanna Meade
NKNicholas Alexander Kennedy
Nicholas Alexander Kennedy
PIPeter M Irving
Peter M Irving
Objective Management of acute severe UC (ASUC) during the novel COVID-19 pandemic presents significant dilemmas. We aimed to provide COVID-19-specific guidance using current British Society of Gastroenterology (BSG) guidelines as a reference point. Design We convened a RAND appropriateness panel comprising 14 gastroenterologists and an IBD nurse consultant supplemented by surgical and COVID-19 experts. Panellists rated the appropriateness of interventions for ASUC in the context of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. Median scores and disagreement index (DI) were calculated. Results were discussed at a moderated meeting prior to a second survey. Results Panellists recommended that patients with ASUC should be isolated throughout their hospital stay and should have a SARS-CoV-2 swab performed on admission. Patients with a positive swab should be discussed with COVID-19 specialists. As per BSG guidance, intravenous hydrocortisone was considered appropriate as initial management; only in patients with COVID-19 pneumonia was its use deemed uncertain. In patients requiring rescue therapy, infliximab with continuing steroids was recommended. Delaying colectomy because of COVID-19 was deemed inappropriate. Steroid tapering as per BSG guidance was deemed appropriate for all patients apart from those with COVID-19 pneumonia in whom a 4–6 week taper was preferred. Post-ASUC maintenance therapy was dependent on SARS-CoV-2 status but, in general, biologics were more likely to be deemed appropriate than azathioprine or tofacitinib. Panellists deemed prophylactic anticoagulation postdischarge to be appropriate in patients with a positive SARS-CoV-2 swab. Conclusion We have suggested COVID-19-specific adaptations to the BSG ASUC guideline using a RAND panel.

6 October 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SASulak Anandabaskaran
Sulak Anandabaskaran
LHLuke Hanna
Luke Hanna
NINusrat Iqbal
Nusrat Iqbal
LCLaura Constable
Laura Constable
PTPhil Tozer
Phil Tozer
AHAilsa Hart
Ailsa Hart
Perianal fistulizing Crohn’s Disease (pCD) affects about 25% of patients with Crohn’s Disease (CD). It remains a difficult entity to manage with a therapeutic ceiling of treatment success despite improving medical and surgical management. The refractory nature of the disease calls for an imminent need to better understand its immunopathogenesis and classification to better streamline our treatment options. In this article, we overview the current state of pCD management and discuss where the future of its management may lie.